Levodopa

Best-known combination/brand name: Levodopa/Carbidopa — historically SinemetOther important Canadian combination: Levodopa/

Benserazide — Prolopa

Levodopa, also called L-DOPA, is the most effective medication for improving the motor symptoms of Parkinson’s disease.

Unlike dopamine itself, levodopa can cross the blood-brain barrier. Once inside the brain, levodopa is converted into: Dopamine

This helps replace some of the dopamine that has been lost as Parkinson’s disease damages dopamine-producing neurons.

Levodopa is almost always given together with either: Carbidopa or: Benserazide

These medications prevent too much levodopa from being converted into dopamine before it reaches the brain.

In Canada, the original Sinemet brand has been discontinued, but several generic levodopa/carbidopa products remain marketed, including APO-LEVOCARB, AURO-LEVOCARB, JAMP LEVOCARB, pms-LEVODOPA-CARBIDOPA and TEVA-LEVOCARBIDOPA.

Prolopa, containing levodopa plus benserazide, also remains marketed in Canada.

What You Need to Know About Levodopa

Levodopa is a:

Dopamine precursor

It is not itself a dopamine receptor agonist.

The basic pathway is:

1. Levodopa is taken
2. Levodopa enters the bloodstream
3. Carbidopa or benserazide prevents excessive conversion to dopamine outside the brain
4. More levodopa reaches the brain
5. Levodopa crosses the blood-brain barrier
6. AADC/DDC converts levodopa into dopamine
7. Dopamine signaling in the basal ganglia increases
8. Parkinson’s motor symptoms may improve

Current Canadian prescribing information describes dopamine depletion in the striatum as central to Parkinsonian motor symptoms. Dopamine itself cannot effectively cross the blood-brain barrier, whereas levodopa can and is then converted into dopamine within the brain.

What Is Levodopa Used For?

Levodopa is primarily used for:

Parkinson’s Disease

It can improve motor symptoms including:

• Slowness of movement — bradykinesia
• Muscle rigidity
• Tremor
• Difficulty initiating movement
• Reduced mobility
• Problems walking
• Difficulty with everyday motor activities Current Canadian levodopa/carbidopa products are indicated for treatment of Parkinson’s disease in adults.

Levodopa is also used in some other forms of parkinsonism, but response may be considerably less predictable than in typical Parkinson’s disease.

It is not generally used to treat drug-induced parkinsonism, because medications causing that condition usually block dopamine receptors rather than cause the same underlying loss of dopamine neurons.

Why Is Dopamine Important in Parkinson’s Disease?

Dopamine-producing neurons in a region of the brain called the:

Substantia Nigra

progressively deteriorate in Parkinson’s disease.

These neurons normally send dopamine to the:

Striatum

which is part of the basal ganglia.

The basal ganglia help regulate:

• Initiation of movement
• Speed of movement
• Smoothness of movement
• Muscle tone
• Motor learning As dopamine-producing neurons are lost:

1. Substantia nigra degeneration
2. Less dopamine reaches the striatum
3. Basal ganglia motor signaling becomes dysregulated
4. Bradykinesia + rigidity + tremor + movement difficulty

Levodopa attempts to restore some of this dopamine signaling.

Why Not Just Give Dopamine?

Dopamine itself cannot effectively cross the: Blood-Brain Barrier — BBB

Therefore, taking dopamine would not efficiently replenish dopamine inside the brain.

Levodopa is different.

It is structurally similar to an amino acid and can use transport systems to cross the blood-brain barrier.

Therefore:

Dopamine

✕

Cannot effectively cross BBB

but:

1. Levodopa
2. Crosses BBB
3. Converted to dopamine inside the brain

This is the fundamental reason levodopa works.

Why Is Levodopa Combined with Carbidopa?

Without carbidopa, much of an oral levodopa dose would be converted into dopamine in the:

Peripheral tissues

before reaching the brain.

This creates two problems:

Less levodopa reaches the brain

and:

Peripheral dopamine causes side effects

such as:

• Nausea
• Vomiting
• Cardiovascular effects Carbidopa blocks the enzyme:

Aromatic L-Amino Acid Decarboxylase — AADC

also called:

DOPA Decarboxylase — DDC

in peripheral tissues.

The result is:

1. Levodopa + carbidopa
2. Peripheral DDC inhibited
3. Less levodopa converted to dopamine outside the brain
4. More levodopa remains available to cross the BBB
5. Levodopa reaches brain
6. Converted to dopamine

Current Canadian labeling states that carbidopa can reduce the amount of levodopa needed for optimal therapeutic benefit by approximately 75–80%, while also reducing nausea, vomiting and some cardiovascular adverse effects related to peripheral dopamine formation.

Does Carbidopa Enter the Brain?

Not to a clinically significant extent.

This is exactly what makes it useful.

Carbidopa primarily inhibits DOPA decarboxylase:

Outside the brain

while allowing levodopa that reaches the brain to be converted into:

Dopamine

Therefore:

Peripheral conversion

→ blocked

but:

Central conversion

→ preserved.

What Is Benserazide?

Benserazide performs a similar function to carbidopa.

It inhibits peripheral DOPA decarboxylase so that more levodopa reaches the brain.

The combination:

Levodopa + Benserazide

is sold in Canada as:

Prolopa

Health Canada lists marketed Prolopa products including 50 mg levodopa/12.5 mg benserazide and 200 mg levodopa/50 mg benserazide strengths.

Both approaches are based on the same principle:

Levodopa provides the dopamine precursor

while:

Carbidopa or benserazide protects levodopa from premature peripheral conversion.

How Effective Is Levodopa for Parkinson’s Disease?

Levodopa remains the most effective medication for improving the motor symptoms of Parkinson’s disease.

It can produce substantial improvement in:

• Bradykinesia
• Rigidity
• Mobility
• Walking
• Motor functioning Tremor may also improve, although response varies.

Levodopa does not cure Parkinson’s disease and does not replace the dopamine-producing neurons that have been lost.

Instead, it provides the remaining brain pathways with the biochemical precursor required to make more dopamine.

Does Levodopa Stop Parkinson’s Disease from Progressing?

No established evidence shows that conventional levodopa treatment stops the underlying neurodegenerative process.

Levodopa is primarily:

Symptomatic treatment

It improves dopamine signaling and function while the medication is active.

The underlying Parkinson’s disease can continue to progress.

This is why medication requirements and treatment patterns often change over time.

What Are the Common Side Effects of Levodopa?

Common or clinically important side effects of levodopa/carbidopa include:

• Nausea
• Vomiting
• Dizziness
• Lightheadedness
• Low blood pressure when standing
• Sleepiness
• Abnormal dreams
• Confusion
• Agitation
• Hallucinations
• Involuntary movements — dyskinesia
• Motor fluctuations
• Changes in blood pressure Canadian patient information identifies nausea, vomiting, sleepiness, dizziness, confusion, agitation and abnormal movements among recognized effects.

What Is Levodopa-Induced Dyskinesia?

One of the most important long-term effects of levodopa is:

Dyskinesia

Dyskinesias are involuntary movements that may appear as:

• Writhing
• Twisting
• Swaying
• Fidgeting
• Jerky movements
• Repetitive movements These movements often occur when brain dopamine concentrations are relatively high.

A simplified mechanism is:

1. Levodopa dose
2. Brain dopamine rises
3. Dopamine stimulation becomes excessive or pulsatile
4. Basal ganglia motor circuits become overactivated
5. Dyskinesia may occur

Current Canadian labeling specifically states that dyskinesia is related to increased brain dopamine and may require dose adjustment.

Dyskinesia should not automatically be interpreted as worsening Parkinson’s disease.

It can indicate that dopaminergic stimulation is excessive at that point in the dosing cycle.

What Is “Wearing Off”?

Levodopa has a relatively short half-life.

When Parkinson’s disease is earlier in its course, remaining dopamine neurons can help buffer fluctuations in dopamine supply.

As the disease progresses, this buffering ability decreases.

A dose may therefore work well for several hours and then begin to fade.

This is called:

Wearing Off

The pattern can look like:

1. Levodopa dose
2. ON period
3. Movement improves
4. Drug concentration falls
5. Wearing off
6. Parkinson's symptoms return before the next dose.

Symptoms may include:

• Slower movement
• Rigidity
• Tremor
• Difficulty walking
• Anxiety or other non-motor symptoms in some patients

What Does “ON” and “OFF” Mean with Levodopa?

ON Time

Levodopa is working well and motor symptoms are controlled.

OFF Time

Levodopa effect has diminished and Parkinson’s symptoms return.

Some patients develop unpredictable transitions between the two states:

1. ON
2. OFF
3. ON again

This is known as the:

ON-OFF Phenomenon

Canadian prescribing information recognizes both levodopa-induced involuntary movements and the “on and off” phenomenon during treatment.

Why Do Motor Fluctuations Develop?

Several factors contribute:

• Levodopa has a short plasma half-life
• Gastric emptying varies
• Food affects absorption
• Protein can compete with levodopa
• The number of surviving dopamine neurons decreases
• The brain becomes less able to store and buffer dopamine
• Receptors and basal ganglia circuits adapt to repeated pulsatile stimulation Therefore, over time:

Plasma levodopa concentration

can more directly determine:

Brain dopamine availability

which can produce alternating:

Too little dopamine → OFF

and:

Too much stimulation → dyskinesia

This is why advanced Parkinson’s treatment often attempts to make dopaminergic stimulation more continuous and stable.

Can Levodopa Cause Hallucinations?

Yes.

Increasing dopamine signaling can sometimes produce:

• Visual hallucinations
• Confusion
• Delusions
• Paranoid thinking Hallucinations are a recognized effect of dopaminergic treatment, including levodopa.

Risk may be greater in:

• Older adults
• Advanced Parkinson’s disease
• People with cognitive impairment
• People taking other dopaminergic medications
• Patients with previous hallucinations or psychosis This illustrates an important principle:

The dopamine increase that improves movement can become excessive or undesirable in other brain pathways.

Can Levodopa Cause Sleepiness?

Yes.

Levodopa/carbidopa can cause:

• Daytime sleepiness
• Somnolence
• Rare episodes of suddenly falling asleep Canadian labeling contains a serious warning about sudden onset of sleep, including cases occurring during activities such as driving.

Patients who experience unexpected sleep episodes or significant daytime sleepiness should discuss this promptly with their healthcare professional.

Can Levodopa Lower Blood Pressure?

Yes.

Levodopa can cause:

Orthostatic hypotension

meaning blood pressure falls when standing.

Symptoms may include:

• Lightheadedness

• Dizziness

• Weakness

• Blurred vision

• Fainting The risk may increase when levodopa is combined with:

• Antihypertensive medications

• Other Parkinson’s medications

• Dehydration Medication doses may need review if significant hypotension develops.

Can Levodopa Affect Behaviour?

Yes, although these effects are more strongly associated with dopamine agonists.

Dopaminergic treatment can occasionally contribute to impulse-control disorders, including:

• Compulsive gambling
• Hypersexuality
• Compulsive shopping
• Binge eating
• Repetitive purposeless behaviour Canadian post-marketing information notes that these behaviours have been reported rarely with levodopa treatment.

Patients and families should mention significant new behavioural changes to the treating clinician.

Can Levodopa Cause Dopamine Dysregulation Syndrome?

Rarely, some patients develop a pattern of compulsive overuse of dopaminergic medication known as:

Dopamine Dysregulation Syndrome

The person may feel driven to take more levodopa than needed to control motor symptoms despite:

• Dyskinesias
• Behavioural changes
• Mood effects
• Social consequences This is not typical medication use and requires specialist management.

Levodopa and Food

Food can have a clinically important effect on levodopa.

One of the most important issues is:

Protein

Levodopa is chemically similar to certain large neutral amino acids.

Dietary proteins are broken down into amino acids that can compete with levodopa for:

• Absorption from the intestine
• Transport toward and across the blood-brain barrier Therefore:

1. High-protein meal
2. More competing amino acids
3. Levodopa absorption or transport may decrease
4. Medication effect may become delayed or weaker

Current Canadian prescribing information states that levodopa absorption may be impaired in some patients consuming a high-protein diet.

Does That Mean Patients Should Avoid Protein?

No.

Protein is nutritionally important.

The issue is often timing and distribution, not eliminating protein.

Some patients with significant motor fluctuations may benefit from discussing with their healthcare professional or dietitian whether levodopa should be taken:

Away from protein-rich meals

or whether protein should be distributed differently throughout the day.

This should be individualized, particularly in older patients where maintaining adequate:

• Protein
• Calories
• Muscle mass is also very important.

Levodopa and Iron

Iron supplements can reduce levodopa absorption.

Iron can bind with levodopa and form complexes in the gastrointestinal tract.

Therefore:

• Iron supplement
• Levodopa

1. Drug-iron complex
2. Less levodopa may be absorbed

Canadian prescribing information confirms that ferrous sulfate can decrease the bioavailability of levodopa and/or carbidopa and notes that other iron supplements and iron-containing multivitamins may have similar effects.

Patients taking iron should ask their pharmacist or physician about appropriate separation of dosing times.

Drug Interactions

Nonselective MAO Inhibitors

Levodopa/carbidopa should not be combined with nonselective monoamine oxidase inhibitors because severe cardiovascular reactions, including hypertension, may occur.

Examples include certain older antidepressant MAO inhibitors.

Current Canadian labeling requires nonselective MAO inhibitors to be stopped at least:

Two weeks before starting levodopa/carbidopa.

Selective MAO-B inhibitors such as selegiline may be used in Parkinson’s disease under appropriate dosing and supervision.

Dopamine D2 Receptor Antagonists

This interaction is particularly important.

Levodopa works by increasing dopamine.

Antipsychotics such as haloperidol block:

D2 dopamine receptors

Therefore:

Levodopa

→ increases dopamine signaling

while:

D2 antagonist

→ blocks dopamine signaling.

The medications can oppose each other.

Canadian labeling identifies D2 antagonists, including phenothiazines, butyrophenones and risperidone, as drugs that may reduce levodopa’s therapeutic effect.

This does not mean antipsychotics can never be used in Parkinson’s disease, but medication choice becomes especially important.

Metoclopramide

Metoclopramide can block dopamine receptors.

Although it may accelerate gastric emptying and potentially alter levodopa absorption, its dopamine antagonism can also:

Worsen Parkinsonian symptoms

or:

Reduce levodopa benefit

Current Canadian labeling advises caution with this combination.

Dopamine-Depleting Medications

Examples include:

• Reserpine
• Tetrabenazine These drugs reduce dopamine availability and can oppose levodopa treatment.

Canadian prescribing information does not recommend concomitant use because levodopa response may decrease.

Antihypertensive Medications

Levodopa can reduce blood pressure.

When it is added to an antihypertensive medication, some patients can experience:

Symptomatic orthostatic hypotension

Blood-pressure medication may occasionally require adjustment.

Tricyclic Antidepressants

Rare reports have described:

• Hypertension
• Dyskinesia when tricyclic antidepressants are combined with levodopa/carbidopa.

The combination may still be used clinically when appropriate, but requires consideration of the complete medication regimen.

Phenytoin and Papaverine

Both have been reported to reduce the beneficial effect of levodopa in some patients.

Patients taking these medications should be monitored for loss of Parkinson’s symptom control.

Vitamin B6 — Pyridoxine

Vitamin B6 can increase the peripheral conversion of levodopa to dopamine by stimulating DOPA decarboxylase activity.

This historically caused a major interaction when:

Levodopa was given alone

However, carbidopa blocks peripheral DOPA decarboxylase and largely prevents this effect.

Current Canadian labeling notes that pyridoxine can reverse levodopa’s effect when used alone, but carbidopa inhibits this interaction.

Patients should still discuss supplements with their healthcare professional.

Levodopa Dosage

There is no single ideal levodopa dose.

Treatment is highly individualized according to:

• Age
• Parkinson’s severity
• Previous levodopa exposure
• Duration of benefit
• Wearing-off symptoms
• Dyskinesia
• Other Parkinson’s medications
• Food effects
• Side-effect sensitivity The goal is:

The lowest dose and schedule that provides useful symptom control without troublesome dyskinesia or other adverse effects.

Levodopa/Carbidopa Dosage in Canada

For one current Canadian immediate-release levodopa/carbidopa product, PRO-LEVOCARB, the labeled initiation regimen in adults who are not already taking levodopa is:

100 mg levodopa / 25 mg carbidopa three times daily

The dose may then be increased carefully in small steps according to response and dyskinesia. The monograph advises that patients should generally not receive more than 1,500 mg of levodopa per day, although dosing remains individualized.

Available Canadian immediate-release combinations include ratios such as:

• 100 mg levodopa / 25 mg carbidopa
• 100 mg levodopa / 10 mg carbidopa

250 mg levodopa / 25 mg carbidopa

This should not be interpreted as a universal starting schedule for every patient or every formulation.

Why Is Carbidopa Dose Important?

Carbidopa must adequately block peripheral DOPA decarboxylase.

Canadian labeling notes that peripheral DOPA decarboxylase is generally saturated at approximately:

70–150 mg of carbidopa per day

and that patients receiving less than about 70 mg/day may be more likely to experience nausea and vomiting.

This is one reason the ratio of:

Levodopa : Carbidopa

matters, not just the total amount of levodopa.

Immediate-Release vs Continuous Levodopa

Most patients begin with oral formulations.

However, in advanced Parkinson’s disease, fluctuating drug concentrations can become difficult to manage.

Canada also has:

DUODOPA

a levodopa/carbidopa intestinal gel delivered continuously into the small intestine for selected patients with advanced levodopa-responsive Parkinson’s disease and severe motor fluctuations.

The objective is to provide more continuous levodopa exposure and reduce extreme peaks and troughs.

Canada also has VYALEV, a continuous subcutaneous formulation using the prodrugs foslevodopa/foscarbidopa for selected advanced Parkinson’s patients with inadequately controlled motor fluctuations.

These are specialist treatments and are very different from ordinary oral levodopa tablets.

Why Does Levodopa Have a Short Duration of Action?

With carbidopa, levodopa’s plasma half-life is approximately:

1.5 hours

compared with about:

50 minutes without carbidopa.

This relatively short half-life contributes to:

• Wearing off
• Dose-to-dose fluctuations
• ON/OFF changes particularly as Parkinson’s disease advances.

Should Levodopa Be Stopped Suddenly?

No, not unless directed urgently by a healthcare professional.

Rapid reduction or sudden withdrawal of dopaminergic treatment can produce a rare but serious syndrome resembling:

Neuroleptic Malignant Syndrome

Possible symptoms include:

• Severe muscle rigidity
• High fever
• Confusion
• Altered consciousness
• Unstable blood pressure or heart rate
• Elevated creatine kinase Canadian labeling specifically reports this syndrome after rapid reduction, withdrawal or major changes in antiparkinsonian treatment.

Patients should not independently:

• Stop levodopa
• Reduce the dose
• Change dosing frequency without discussing it with their treating clinician.

Can Pharmacogenomic Testing Tell Whether Levodopa Will Work?

Levodopa response depends on many factors, including:

• Degree of dopamine deficiency
• Remaining nigrostriatal neurons
• Intestinal absorption
• Gastric emptying
• Protein intake
• Drug interactions
• DDC activity
• COMT activity
• Dopamine transport
• Dopamine receptor biology
• Disease stage
• Dose timing There is currently no genetic result that reliably provides a simple:

“Levodopa will work”

or:

“Levodopa will not work.”

Levodopa response is better assessed by integrating:

clinical response + motor symptoms + pharmacology + medication exposure + individual biology

rather than relying on one variant.

Frequently Asked Questions

Is Levodopa the Same as Sinemet?

Not exactly.

Levodopa

is the dopamine precursor.

Sinemet

was the best-known brand containing:

Levodopa + carbidopa

The original Sinemet brand is no longer marketed in Canada, but several generic levodopa/carbidopa products remain available.

Is Levodopa the Same as Carbidopa?

No.

Levodopa:

crosses into the brain and becomes dopamine

Carbidopa:

prevents levodopa from being converted to dopamine too early outside the brain.

They perform very different but complementary roles.

Is Levodopa the Same as Dopamine?

No.

Levodopa is:

the metabolic precursor of dopamine

The brain converts levodopa into dopamine.

Does Levodopa Increase Dopamine?

Yes.

That is its main therapeutic purpose.

1. Levodopa
2. Crosses the BBB
3. Converted by AADC/DDC
4. Brain dopamine increases

Why Is Levodopa Considered the Gold-Standard Parkinson’s Medication?

Because it generally produces the strongest improvement in the core motor symptoms of Parkinson’s disease, particularly:

• Bradykinesia
• Rigidity
• Mobility impairment It remains the central dopamine-replacement treatment in Parkinson’s disease.

Does Levodopa Help Tremor?

It often can, although tremor response varies more between individuals than improvement in bradykinesia and rigidity.

Does Levodopa Cure Parkinson’s Disease?

No.

It improves symptoms by increasing dopamine availability but does not restore the lost dopamine-producing neurons.

Why Does Levodopa Stop Working Before the Next Dose?

This is called:

Wearing off

and may occur because levodopa has a short half-life and the progressively affected brain becomes less capable of storing and buffering dopamine.

Why Does Levodopa Cause Dyskinesia?

Levodopa can sometimes produce excessive or fluctuating dopamine stimulation of motor circuits.

The result may be involuntary movements, especially near periods of high drug exposure.

Can Levodopa Cause Hallucinations?

Yes.

Dopamine signaling is involved in more than movement. Excessive stimulation in other brain systems can contribute to hallucinations, confusion or psychotic symptoms.

Should Levodopa Be Taken with Food?

It depends.

Food can reduce nausea, but protein can reduce or delay levodopa absorption in some patients.

Patients with significant fluctuations may need individualized advice about timing levodopa relative to meals.

Can Protein Affect Levodopa?

Yes.

Dietary amino acids can compete with levodopa for transport, potentially reducing or delaying its effect.

Can Iron Affect Levodopa?

Yes.

Iron can bind levodopa and reduce its bioavailability.

Can Haloperidol Affect Levodopa?

Yes.

Haloperidol blocks D2 dopamine receptors and can therefore oppose levodopa’s dopaminergic effect.

Strong D2-blocking antipsychotics can worsen Parkinsonian motor symptoms.

Does Levodopa Need to Be Tapered?

Major dose reductions or discontinuation should generally be medically supervised.

Rapid withdrawal can rarely produce severe rigidity, fever, mental changes and autonomic instability resembling neuroleptic malignant syndrome.

Which Genes Are Most Relevant to Levodopa?

Important biological candidates include:

• DDC
• COMT
• SLC6A3
• DRD2
• DRD3
• MAOA
• MAOB However, none currently provides an established CPIC- or DPWG-style levodopa dosing algorithm.

Does COMT rs4680 Determine the Levodopa Dose?

No.

COMT rs4680 is biologically relevant and has been associated with differences in levodopa response in some studies, but results are inconsistent.

It should not currently be used alone to determine a levodopa dose.

Can Pharmacogenomic Testing Predict Levodopa Dyskinesia?

Not reliably enough for routine clinical prescribing at present.

Multiple genes have been associated with dyskinesia in individual studies, but large analyses show considerable inconsistency.

References

• [https://health-products.canada.ca/dpd-bdpp/search-fast-recherche-rapide?lang=eng&no=0210315001&no=0210315001)
• [https://health-products.canada.ca/dpd-bdpp/info?code=2724&lang=eng&lang=eng)
• https://pdf.hres.ca/dpd_pm/00084978.PDF